Chenyu Lin

Medical Director, Cellular Therapy Program

Hematologic oncologist specializing in the care of patients with acute leukemias and aggressive lymphomas, and those patients who require administration of an immune effector cellular therapy. Dr. Lin oversees Duke's cellular therapy program, which provides cell-based treatments such as chimeric antigen receptor T (CAR T) cell therapy, engineered T cell receptor (TCR) therapy, and tumor infiltrating lymphocytes (TILs) for a variety of cancers and autoimmune disorders. His research interests include clinical trials, digital health, and real-world evidence.

Fellowship: Duke Cancer Institute
Residency: Northwestern University
Medical School: University of Chicago Pritzker School of Medicine
Undergraduate: Yale University